메뉴 건너뛰기




Volumn 48, Issue , 2013, Pages 421-434

Case History. Xalkori (Crizotinib), a Potent and Selective Dual Inhibitor of Mesenchymal Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) for Cancer Treatment.

Author keywords

ALK; Crizotinib; EML4 ALK; HGF; MET; PF 02341066; Receptor tyrosine kinase; ROS; Xalkori

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; AXITINIB; CRIZOTINIB; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; STAT PROTEIN; SUNITINIB; UNCLASSIFIED DRUG;

EID: 84884158867     PISSN: 00657743     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-417150-3.00025-9     Document Type: Chapter
Times cited : (27)

References (42)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.